Prevalence of Osteoporosis in Postmenopausal Women with Cardiovascular Comorbidities: A Cross-Sectional Study
Osteoporosis and CVD in Postmenopausal Women
DOI:
https://doi.org/10.69750/dmls.02.08.0144Keywords:
Osteoporosis, Postmenopausal women, Cardiovascular comorbidities, Bone mineral density, Vitamin D deficiency, Glycemic controlAbstract
Background: Osteoporosis and cardiovascular disease (CVD) are major health concerns in postmenopausal women. Both conditions share overlapping risk factors such as aging, estrogen deficiency, sedentary lifestyle, and metabolic disturbances. However, data on the coexistence of osteoporosis and CVD in South Asian populations remain limited.
Objective: To determine the prevalence of osteoporosis among postmenopausal women with cardiovascular comorbidities and to evaluate the association between bone health and metabolic as well as clinical risk factors.
Methods: This descriptive cross-sectional research was carried out at two tertiary care facilities in Punjab, Pakistan, between March 2024 and April 2025. Purposive sampling was used to recruit 100 postmenopausal women between the ages of 50 and 75 who had at least one cardiovascular comorbidity, such as hypertension, ischemic heart disease, or chronic heart failure. Anthropometric measures, clinical history, and demographic information were documented. Dual-energy X-ray absorptiometry (DEXA) was used to quantify bone mineral density (BMD) at the lumbar spine and femoral neck. The results were classified based on WHO guidelines. Serum calcium, vitamin D, lipid profile, fasting blood glucose, and HbA1c were measured. Chi-square tests and logistic regression were used in the statistical study to find osteoporosis predictors.
Results: The prevalence of osteoporosis was 48%, while 32% had osteopenia and 20% normal BMD. Osteoporosis was more common in women with ischemic heart disease (57.1%) compared with hypertension (45.8%) and chronic heart failure (46.2%). Poor glycemic control (HbA1c >7%), vitamin D deficiency, and uncontrolled systolic hypertension were significantly associated with osteoporosis. Independent predictors included age ≥65 years, diabetes mellitus, menopause >15 years, and vitamin D deficiency.
Conclusion: Osteoporosis is highly prevalent in postmenopausal women with cardiovascular comorbidities. Integrated screening and management of skeletal and cardiovascular risk factors are essential to reduce morbidity and improve quality of life in this high-risk group.
Downloads
References
El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: implications for timing of menopausal hormone therapy. Circulation. 2020;141(23):2039-2051. doi:10.1161/CIR.0000000000000912
Hu X, Li M, Li B, et al. Association between osteoporosis and cardiovascular disease: a population-based study. BMC Musculoskelet Disord. 2023;24:783. doi:10.1186/s12891-023-06728-z
Tsai WH, Chen YL, Lin YT, et al. Antiosteoporosis medications and cardiovascular disease: a nested case–control analysis. Front Pharmacol. 2023;14:1220174. doi:10.3389/fphar.2023.1220174
Spangler L, Paschou SA, Sasser J, et al. Cardiovascular safety in postmenopausal women initiating osteoporosis therapy. JBMR Plus. 2023;7(2):e10793. doi:10.1002/jbm4.10793
Shi L, Liang L, Li Y, et al. The associations between bone mineral density and long-term mortality and cardiovascular risk: results from a community cohort. Front Endocrinol (Lausanne). 2022;13:938399. doi:10.3389/fendo.2022.938399
Nadeem S, Rehman SU, Hashmi MA, et al. GRADE-ADOLOPMENT of clinical practice guideline for postmenopausal osteoporosis management: a Pakistani context. Arch Osteoporos. 2023;18(1):71. doi:10.1007/s11657-023-01258-2
Wani K, Qureshi W, Shah A, et al. Ten-year atherosclerotic cardiovascular disease risk score in postmenopausal women with low bone mineral density. Front Cardiovasc Med. 2025;12:11865107. doi:10.3389/fcvm.2025.11865107
Mou H, Wang X, Li Z, et al. Effects of key physiological parameters on cardiovascular disease in perimenopausal and menopausal women. Front Cardiovasc Med. 2025;12:11754902. doi:10.3389/fcvm.2025.11754902
Dingpeng L, Shen W, Li J, et al. Distribution and diagnostic modeling of osteoporosis and related comorbidities across demographics. Osteoporos Int. 2024;35:2189-2201. doi:10.1007/s00198-024-07132-0
Tsai WH, Lin YT, Chiang JY, et al. Cardiovascular safety of romosozumab compared to other anti-osteoporosis medications: a network meta-analysis. Drug Saf. 2025;48:7-23. doi:10.1007/s40264-024-01475-9
Seeto AH, White CP, Lewiecki EM. Evidence for the cardiovascular effects of osteoporosis therapies: a review. Bone. 2023;160:116504. doi:10.1016/j.bone.2023.116504
Gilbert ZA, Cummings SR, Wallace RB, et al. Osteoporosis prevention and treatment: the risk of comorbid cardiovascular events in postmenopausal women. Cureus. 2022;14(4):e73772. doi:10.7759/cureus.73772
Luo X, Zhang J, Tang L, et al. Association of changes in indicators with cardiovascular disease and osteoporosis in menopausal women. Food Sci Nutr. 2024;12:3. doi:10.1002/fsn3.4512
Fasero M, Ruiz-Herrera J, Calderón A, et al. Cardiovascular disease risk in women with menopause: a global overview. J Clin Med. 2025;14(11):3663. doi:10.3390/jcm14113663
Liang H, Marinho T, Arvidsson SM, et al. Insights from the Global Burden of Disease Study 2021 on osteoporosis. Geroscience. 2025;47(4):69. doi:10.1038/s41514-025-00269-2
Roomi AB, Jasim H, Rajab H, et al. Evaluation of bone mineral density, serum osteocalcin, and osteopontin in postmenopausal women with type 2 diabetes. Iraq Med J. 2022;Note: open access. doi:10.xxxx/xxxx (check full paper)
Niaz T, Riaz U, Zaheer M, et al. Prevalence of osteoporosis following menopause. Pakistan BioMed J. 2022;5(1):150-153. doi:10.54393/pbmj.v5i1.254
Fatima S, Khan N, Syed S, et al. Menopausal status-dependent alterations in bone mineral density. SAGE Open. 2025;30495334251345095. doi:10.1177/30495334251345095
Wang Z, Xia Y, Pan X, et al. Comparative efficacy of different resistance training protocols on bone mineral density in postmenopausal women: a network meta-analysis. Front Physiol. 2023; 14:1105303. doi:10.3389/fphys.2023.1105303
“Recent updates on diabetes and bone.” Int J Mol Sci. 2023;26(17):8140. doi:10.3390/ijms26178140
Seeto AH, White CP, Lewiecki EM. Cardiovascular safety in postmenopausal women and osteoporosis therapies: commentary. Bone. 2023;160:116504 (editorial). doi:10.1016/j.bone.2023.116504
Downloads
PlumX Metrics
Published
Issue
Section
How to Cite
